Molecular Systems Architecture of Fibrotic Lung Microenvironment in Idiopathic Pulmonary Fibrosis

Our plain-English summary of Molecular Systems Architecture of Fibrotic Lung Microenvironment in Idiopathic Pulmonary Fibrosis, by V.A.S. Ayyadurai, Y. Manoharan, P. Deonikar (Cells, 2026).

The study

• Authors: V.A.S. Ayyadurai, Y. Manoharan, P. Deonikar
• Journal: Cells
• Published: 2026;15(15)
• Type of article: Systematic review
• Read it: PubMed · Publisher · Free full text

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible fibrosing interstitial lung disease characterized by excessive extracellular matrix (ECM) accumulation, disruption of lung architecture, and progressive loss of pulmonary function. IPF is frequently accompanied by comorbid conditions that exacerbate disease progression and negatively impact prognosis. To address the biological complexity of IPF, this study presents a comprehensive molecular systems architecture that enables a system-level understanding of biomolecular interactions within the fibrotic lung microenvironment in response to external and physiological triggers. Methods: A literature search is conducted using the Medical Subject Headings (MeSH) keywords in PubMed and MEDLINE to identify relevant peer-reviewed articles published from April 2008 to June 2025, with Google Scholar used solely to retrieve full-text versions of articles identified through this search. The systems biology tool CytoSolve® was used to perform the systematic review and to support the curation and development of the molecular systems architecture of IPF pathogenesis. Full-length articles that contained Medical Subject Headings keywords relevant to IPF pathogenesis were selected for a comprehensive review. A total of 150 studies published between April 2008 and June 2025 met the inclusion criteria and were included in the systematic analysis. This systematic review was not registered. Results: Findings were synthesized qualitatively into a multilayered molecular interactome rather than through statistical meta-analysis. The architecture integrates interactions across sixteen lung-associated cell types, including epithelial, endothelial, mesenchymal, immune, and stromal populations. Key external triggers-such as bleomycin (BLM), asbestos, silica, radiation, cigarette smoke, Herpes virus, and genetic mutations (SFTPC I73T), along with hypoxia associated with comorbidities-initiate coordinated cellular responses that converge on three fundamental pathological processes: inflammation, myofibroblast differentiation, and tissue remodeling. These interconnected processes collectively drive the initiation and progression of IPF. Conclusions: This molecular systems architecture unifies triggers, cellular components, molecular pathways, and biological processes into a multilayered framework for identifying therapeutic targets, biomarkers, and rational single- and combination-treatment strategies in IPF.

In plain English

This article is a systematic literature review, not a new experiment. The authors searched PubMed for idiopathic pulmonary fibrosis (IPF) studies from April 2008 to June 2025. Of 1555 records found, 150 were included. Using their CytoSolve tool, the authors combined the reported pathways into a map of how lung cells signal to one another. They did not pool results statistically. Asbestos is mentioned briefly: as a pollutant that injures the lung lining, and as one trigger in the animal studies behind the map. The article names no asbestos fiber type and has no asbestos data of its own. It cites studies reporting that the NLRP3 inflammasome, an inflammatory protein complex, is activated in models induced by asbestos, silica and bleomycin. The map covered sixteen cell types and twenty-seven molecular pathways. These converged on three processes: inflammation, myofibroblast differentiation and tissue remodeling. TGF-beta was described as the central hub. The authors listed thirty-four possible drug targets. They noted that the map is static, that animal findings may not apply to humans, and that its causal wording reflects cited studies, not statistical testing.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Systematic literature review (mechanistic pathway curation, reported following PRISMA 2020, not registered) with qualitative synthesis into a molecular interaction map; no statistical meta-analysis
• Who was studied: Published studies, not people: 1555 records identified in PubMed, 358 duplicates removed, 1197 screened, 714 assessed in full text, and 150 studies published April 2008 to June 2025 included
• Exposure: Triggers of IPF drawn from animal-model studies: bleomycin (BLM), asbestos, silica, radiation, cigarette smoke, herpes virus and genetic mutations, plus hypoxia from obstructive sleep apnea. No asbestos fiber type, product, job or dose is specified.
• Main results:
  • The map links sixteen lung cell types through twenty-seven molecular pathways (one passage states twenty-eight).
  • The pathways were organized as converging on three biological processes of IPF.
  • TGF-beta was described as the central profibrotic hub, modulating ten of the pathways.
  • Citing other literature, the review describes asbestos as a pollutant trigger. Together with silica, it appears in a list that also includes cigarette smoke, microbial infection and drugs, all described as causing repeated inflammation and damage to the lung lining when exposure recurs.
  • Citing other studies, the review states that the NLRP3 inflammasome is activated in IPF models induced by asbestos, silica and bleomycin. This is a finding of the cited studies, not of this review.
  • Thirty-four candidate molecular targets were identified within the pathways.
  • Of the 34 targets:
• 17 were linked only to myofibroblast differentiation.
• 8 were linked only to tissue remodeling.
• 1 was linked only to inflammation.
• The remaining 8 were linked to more than one process.
  • Under a literature-frequency weighting (number of supporting references and number of processes), TGF-beta (three references, two processes) and galectin-3, YAP1 and autotaxin (two references each, two processes) scored highest.
• The authors' conclusion: The authors concluded that the architecture may enable discovery of combination therapies that act on more than one molecular target affecting multiple disease processes. They also concluded that it provides a framework for identifying therapeutic targets and biomarkers, and for building future computer models.
• Limitations the authors state:
  • Limiting the search to literature from 2008 to 2025 may underrepresent very recent advances.
  • The causal wording in the map reflects mechanisms reported in the cited studies, not statistically tested causation.
  • The map does not assign the same level of confidence to every interaction it shows.
  • How much each pathway contributes may differ between patient subgroups and clinical settings.
  • The mechanisms linking the lung and the brain are less well characterized than the externally driven pathways.
  • The map is static. Dynamic computer simulation has not yet been done.
  • The map does not show where the cells are physically located in lung tissue.
  • Findings from mouse models, including the bleomycin model, cannot be fully translated to humans.

Topics

Medical terms in this study, explained in our Lexicon: Idiopathic, Pulmonary Fibrosis, Interstitial Lung Disease, Disease Progression, Prognosis, Systematic Review, Meta-Analysis, Hypoxia.

Related studies

• The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease — F. Khan, I. Stewart, et al. (2019)
• Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis — K.A. Khan, M.P. Kennedy, et al. (2015)
• Loss of ANT1 Increases Fibrosis and Epithelial Cell Senescence in Idiopathic Pulmonary Fibrosis — J. Sui, J.C. Boatz, et al. (2023)
• The comparison of high-resolution computed tomography findings in asbestosis and idiopathic pulmonary fibrosis — M. Akira, K. Morinaga (2016)
• Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control study — M.J. Abramson, T. Murambadoro, et al. (2020)
• Imaging in idiopathic pulmonary fibrosis: diagnosis and mimics — B. Hochhegger, E. Marchiori, et al. (2019)

Browse more research in Cells, or return to medical research.